Marinus Pharmaceuticals Company Profile (NASDAQ:MRNS)

About Marinus Pharmaceuticals (NASDAQ:MRNS)

Marinus Pharmaceuticals logoMarinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy. Marinus Pharmaceuticals, Inc. was granted orphan status for its two drugs on June 29, 2017.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:MRNS
  • CUSIP: N/A
  • Web:
  • Market Cap: $43.94 million
  • Outstanding Shares: 22,420,000
Average Prices:
  • 50 Day Moving Avg: $1.43
  • 200 Day Moving Avg: $1.38
  • 52 Week Range: $0.82 - $2.73
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.06
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.88 per share
  • Price / Book: 2.23
  • EBIDTA: ($26,500,000.00)
  • Return on Equity: -119.58%
  • Return on Assets: -83.18%
  • Debt-to-Equity Ratio: 0.05%
  • Current Ratio: 3.91%
  • Quick Ratio: 3.91%
  • Average Volume: 321,971 shs.
  • Beta: 2.04
  • Short Ratio: 8.92
Frequently Asked Questions for Marinus Pharmaceuticals (NASDAQ:MRNS)

What is Marinus Pharmaceuticals' stock symbol?

Marinus Pharmaceuticals trades on the NASDAQ under the ticker symbol "MRNS."

How were Marinus Pharmaceuticals' earnings last quarter?

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) announced its earnings results on Monday, May, 1st. The company reported ($0.26) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.32) by $0.06. View Marinus Pharmaceuticals' Earnings History.

Where is Marinus Pharmaceuticals' stock going? Where will Marinus Pharmaceuticals' stock price be in 2017?

1 analysts have issued twelve-month price targets for Marinus Pharmaceuticals' shares. Their forecasts range from $3.00 to $3.00. On average, they expect Marinus Pharmaceuticals' share price to reach $3.00 in the next twelve months. View Analyst Ratings for Marinus Pharmaceuticals.

Who are some of Marinus Pharmaceuticals' key competitors?

Who are Marinus Pharmaceuticals' key executives?

Marinus Pharmaceuticals' management team includes the folowing people:

  • Christopher M. Cashman, Chairman of the Board, President, Chief Executive Officer
  • Lorianne K. Masuoka M.D., Chief Medical Officer
  • Edward F. Smith, Chief Financial Officer, Vice President, Treasurer, Secretary
  • Michael R. Dougherty, Director
  • Seth H. Z. Fischer, Director
  • Enrique J. Carrazana M.D., Independent Director
  • Timothy M. Mayleben, Independent Director
  • Jay P. Shepard, Independent Director

How do I buy Marinus Pharmaceuticals stock?

Shares of Marinus Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Marinus Pharmaceuticals' stock price today?

One share of Marinus Pharmaceuticals stock can currently be purchased for approximately $1.96.

MarketBeat Community Rating for Marinus Pharmaceuticals (NASDAQ MRNS)
Community Ranking:  3.1 out of 5 (  )
Outperform Votes:  101 (Vote Outperform)
Underperform Votes:  60 (Vote Underperform)
Total Votes:  161
MarketBeat's community ratings are surveys of what our community members think about Marinus Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Marinus Pharmaceuticals (NASDAQ:MRNS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.00 (53.06% upside)

Analysts' Ratings History for Marinus Pharmaceuticals (NASDAQ:MRNS)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/3/2016Jefferies Group LLCReiterated RatingBuy$3.00N/AView Rating Details
6/28/2016Stifel NicolausReiterated RatingHoldN/AView Rating Details
6/14/2016Goldman Sachs Group, Inc. (The)DowngradeBuy -> NeutralN/AView Rating Details
6/14/2016Oppenheimer Holdings, Inc.DowngradeOutperform -> Market PerformN/AView Rating Details
6/14/2016Royal Bank Of CanadaDowngradeOutperform -> Sector Perform$14.00 -> $2.00N/AView Rating Details
(Data available from 7/27/2015 forward)


Earnings History for Marinus Pharmaceuticals (NASDAQ:MRNS)
Earnings by Quarter for Marinus Pharmaceuticals (NASDAQ:MRNS)
Earnings History by Quarter for Marinus Pharmaceuticals (NASDAQ MRNS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2017Q1 2017($0.32)($0.26)ViewN/AView Earnings Details
3/13/2017Q4 2016($0.33)($0.31)ViewN/AView Earnings Details
11/3/2016Q3($0.43)($0.33)ViewN/AView Earnings Details
8/9/2016Q2($0.38)($0.46)ViewN/AView Earnings Details
5/2/2016Q1 2016($0.41)($0.37)ViewN/AView Earnings Details
3/7/2016Q416($0.38)($0.45)ViewN/AView Earnings Details
10/29/2015Q3 2015($0.51)($0.35)ViewN/AView Earnings Details
8/4/2015Q2 2015($0.51)($0.37)ViewN/AView Earnings Details
5/11/2015Q1 2015($0.47)($0.50)ViewN/AView Earnings Details
11/13/2014Q3 14($0.50)($0.30)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Marinus Pharmaceuticals (NASDAQ:MRNS)
2017 EPS Consensus Estimate: ($0.89)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.27)($0.27)($0.27)
Q2 20171($0.26)($0.26)($0.26)
Q3 20171($0.18)($0.18)($0.18)
Q4 20171($0.18)($0.18)($0.18)
(Data provided by Zacks Investment Research)


Dividend History for Marinus Pharmaceuticals (NASDAQ:MRNS)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Marinus Pharmaceuticals (NASDAQ:MRNS)
Insider Ownership Percentage: 6.40%
Institutional Ownership Percentage: 32.69%
Insider Trades by Quarter for Marinus Pharmaceuticals (NASDAQ:MRNS)
Institutional Ownership by Quarter for Marinus Pharmaceuticals (NASDAQ:MRNS)
Insider Trades by Quarter for Marinus Pharmaceuticals (NASDAQ:MRNS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/20/2016Anand MehraMajor ShareholderSell750,683$1.39$1,043,449.37View SEC Filing  
8/8/2016Vii Lp CanaanMajor ShareholderSell149,154$1.50$223,731.00View SEC Filing  
8/4/2016Vii Lp CanaanMajor ShareholderSell145,583$1.50$218,374.50View SEC Filing  
7/29/2016Vii Lp CanaanMajor ShareholderSell24,540$1.71$41,963.40View SEC Filing  
7/27/2016Vii Lp CanaanMajor ShareholderSell20,589$1.81$37,266.09View SEC Filing  
7/26/2016Vii Lp CanaanMajor ShareholderSell20,380$1.81$36,887.80View SEC Filing  
7/25/2016Vii Lp CanaanMajor ShareholderSell270,750$1.90$514,425.00View SEC Filing  
4/21/2015Gail M FarfelInsiderSell30,000$9.48$284,400.00View SEC Filing  
8/5/2014Domain Partners Vi, L.P.Major ShareholderBuy419,744$8.00$3,357,952.00View SEC Filing  
8/5/2014Stephen M BlochDirectorBuy625,000$8.00$5,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Marinus Pharmaceuticals (NASDAQ:MRNS)
Latest Headlines for Marinus Pharmaceuticals (NASDAQ:MRNS)
DateHeadline logoComparing Marinus Pharmaceuticals (NASDAQ:MRNS) & BioDelivery Sciences International (BDSI) - July 22 at 8:02 AM logoMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Downgraded by ValuEngine to "Strong Sell" - July 16 at 4:34 PM logoMarinus Pharmaceuticals, Inc. (MRNS) Rating Lowered to Strong Sell at ValuEngine - July 7 at 5:47 PM logoMarinus' (MRNS) Ganaxolone Gets Orphan Drug Status in US - July 1 at 2:33 AM logoMarinus Pharma (MRNS) Says FDA Grants Orphan Drug ... - - June 30 at 1:51 AM logoFDA Grants Orphan Drug Designation for Ganaxolone in CDKL5 Disorder - June 30 at 1:51 AM logoMarinus Pharma (MRNS) Launches Ganaxolone Clinical Program in Patients with PPD - - June 28 at 10:08 AM logoMarinus Pharma (MRNS) Launches Ganaxolone Clinical Program in Patients with PPD - June 27 at 11:47 PM logoMarinus Pharmaceuticals Launches the Ganaxolone Clinical Program in Patients with Postpartum Depression - June 27 at 6:46 PM logoMarinus Pharmaceuticals, Inc. (MRNS) Upgraded to Sell at ValuEngine - June 20 at 11:40 PM logoShort Interest in Marinus Pharmaceuticals Inc (MRNS) Drops By 4.3% - June 10 at 2:22 PM logoMarinus Pharmaceuticals Inc (MRNS) Receives Average Rating of "Hold" from Analysts - May 29 at 8:38 AM logoHow These Biotech Stocks are Faring? -- Auris Medical, Eleven Biotherapeutics, Inotek Pharma, and Marinus Pharma - PR Newswire (press release) - May 18 at 8:24 AM logoMarinus Pharmaceuticals (MRNS) Receiving Favorable Media Coverage, Analysis Finds - May 3 at 6:46 PM logoMarinus Pharmaceuticals Inc (MRNS) Releases Earnings Results, Beats Expectations By $0.06 EPS - May 2 at 11:20 AM logoMarinus Pharmaceuticals Inc (MRNS) Receives Consensus Rating of "Hold" from Analysts - May 2 at 8:04 AM logoMarinus Pharmaceuticals Provides Business Update and Reports First Quarter 2017 Financial Results - May 1 at 12:31 PM logoMarinus Pharmaceuticals posts 1Q loss - May 1 at 12:31 PM logoMarinus Pharmaceuticals (MRNS) Earns Daily Coverage Optimism Rating of -0.12 - April 30 at 9:38 AM logoMarinus Pharmaceuticals (MRNS) Getting Positive News Coverage, Study Shows - April 27 at 2:24 PM logo-$0.27 EPS Expected for Marinus Pharmaceuticals Inc (MRNS) This Quarter - April 27 at 1:11 AM logoMarinus Pharma (MRNS) to Present Ganaxolone DATA at AAN - - April 20 at 9:55 AM logoMarinus Pharma (MRNS) to Present Ganaxolone DATA at AAN - April 18 at 10:19 AM logoMarinus to present Ganaxolone DATA at American academy of neurology annual meeting - April 18 at 10:19 AM logoMarinus Pharmaceuticals (MRNS) Earns Daily Media Impact Score of 0.39 - April 13 at 3:18 PM logoMarinus Pharma (MRNS) Announces Lorianne Masuoka as New Chief Medical Officer - - April 13 at 8:32 AM logoDr. Lorianne K. Masuoka Joins Marinus Pharmaceuticals as Chief Medical Officer - April 11 at 11:09 AM logoGanaxolone IV Clinical Data Presented at Leading International Status Epilepticus Medical Conference - April 10 at 10:23 AM logoMarinus Pharmaceuticals Inc (MRNS) Expected to Announce Quarterly Sales of $0.00 - April 7 at 5:44 PM logoZacks: Brokerages Expect Marinus Pharmaceuticals Inc (MRNS) Will Announce Earnings of -$0.27 Per Share - April 5 at 4:07 PM logoMarinus Pharmaceuticals Inc (MRNS) Given Average Rating of "Hold" by Brokerages - April 5 at 10:04 AM logoUltragenyxs’ Seizure Drug Fails Study - March 23 at 7:09 PM logoMARINUS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a - March 22 at 6:44 PM logoMARINUS PHARMACEUTICALS INC Financials - March 16 at 7:22 PM logoMarinus Pharmaceuticals to Present at Oppenheimer Healthcare Conference - March 15 at 6:51 PM logoMarinus Pharmaceuticals Inc (MRNS) Expected to Post Q1 2017 Earnings of ($0.27) Per Share - March 15 at 10:11 AM logoMarinus Pharmaceuticals Provides Business Update and 2016 Financial Results - March 13 at 10:16 AM logoMARINUS PHARMACEUTICALS INC Files SEC form 10-K, Annual Report - March 13 at 10:16 AM logoTechnical Reports on Biotech Stocks -- ZIOPHARM Oncology, Aurinia Pharma, Arena Pharma, and Marinus Pharma - February 28 at 10:13 AM logoMarinus Pharma (MRNS) Says Study Shows Ganaxolone Reduces ... - - February 14 at 8:15 PM logoGanaxolone Reduces Seizures and Improves Behaviors in Angelman Syndrome Preclinical Model - February 14 at 8:15 PM logo7:31 am Marinus Pharmaceuticals announces the publication of preclinical data in the January issue of Neuropharmacology, showing that its positive allosteric modulator of GABAa, ganaxolone ameliorates many of the behavioral abnormalities in - February 14 at 8:15 PM logoMARINUS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E - February 8 at 7:32 PM logoMarinus Appoints Michael R. Dougherty to its Board of Directors - GlobeNewswire (press release) - February 1 at 7:43 PM logoMarinus Appoints Michael R. Dougherty to its Board of Directors - February 1 at 7:43 PM logoForm 8-K MARINUS PHARMACEUTICALS For: Jan 23 - January 24 at 7:23 PM logoMid-Day Market Update: Marinus Pharma Surges Following ... - Nasdaq - January 24 at 5:01 AM logoBUZZ-U.S. STOCKS ON THE MOVE-Qualcomm, Halliburton, Marinus Pharma - Nasdaq - January 24 at 5:01 AM logoMarinus Pharma (MRNS) Announes Positive Preliminary Data from CDKL5 Patients Enrolled in Ongoing Phase 2 ... - - January 24 at 5:01 AM logoMarinus Spikes on Positive Seizure Drug Data (MRNS) - January 23 at 6:58 PM



Marinus Pharmaceuticals (MRNS) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by Staff